In the increasingly crowded PD-(L)1 inhibitors market, KEYTRUDA maintains a dominant position, holding more than 50% market share in 2023 it is deeply entrenched with approval across 20 indications. Among the 10 approved drugs, early entrants OPDIVO and KEYTRUDA continue to command a major share of the market. LAS VEGAS , July 2, 2024 /PRNewswire/ -- DelveInsight's PD-(L)1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PD-(L)1 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ].
Key Takeaways from the PD-(L)1 Inhibitors Market Report According to DelveInsight's analysis, the market size of PD-(L)1 inhibitors in the 7MM was nearly USD 36 billion in 2023, and the largest market size was generated by the United States . In the competitive landscape of PD-1 inhibitors, KEYTRUDA dominates the US market, while OPDIVO leads in Japan . LIBTAYO is the market leader for non-melanoma skin cancers, such as cutaneous squamous cell carcinoma and basal cell carcinoma, and is expected to maintain its dominance in the coming years.
TECENTRIQ holds the leading position in small-cell lung cancer. NSCLC is the leading indication for PD-(L)1 inhibitors in the 7MM with total incident cases of nearly ∼ 200,000 in 2023, which is expected to increase by.
